Novartis: to team up with Harvard on immunotherapies
(CercleFinance.com) - Novartis is teaming up with Harvard to develop next-generation biomaterial systems to deliver immunotherapies, the Swiss biopharmaceutical company said on Tuesday.
The Basel-based firm plans to collaborate with scientists from the Wyss Institute at Harvard University and the Dana-Farber Cancer Institute to develop biomaterial systems for its portfolio of immuno-oncology therapies.
These licensed biomaterial systems aim to overcome barriers that have hampered traditional cancer vaccines, the drugmaker said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The Basel-based firm plans to collaborate with scientists from the Wyss Institute at Harvard University and the Dana-Farber Cancer Institute to develop biomaterial systems for its portfolio of immuno-oncology therapies.
These licensed biomaterial systems aim to overcome barriers that have hampered traditional cancer vaccines, the drugmaker said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.